| Code | CSB-MP008540HU1 |
| Abbreviation | Recombinant Human FCGR2A protein, partial (Active) |
| MSDS | |
| Size | $9.9 |
| Promotion | |
| Order now | |
| Image |
|
| Have Questions? | Leave a Message or Start an on-line Chat |
FCGR2A mediates antibody-dependent cellular phagocytosis and cytotoxicity by binding the Fc region of IgG, making it a critical node in immune effector function and a key target for therapeutic antibody engineering. This mammalian-expressed construct spanning residues 34–217 captures the complete extracellular ligand-binding domain, and its native glycosylation pattern supports physiologically relevant interactions with IgG and anti-FCGR2A antibodies, as demonstrated by an EC50 of 24.44–32.57 ng/mL in functional ELISA. The protein meets the quality thresholds commonly required for ligand-binding assays, competitive inhibition screening, and therapeutic antibody epitope mapping, with purity exceeding 95% by SDS-PAGE and endotoxin levels below 1.0 EU/μg. Researchers conducting SPR or BLI affinity characterization, blocking antibody validation, or ADCC mechanism studies will find this construct provides a suitable basis for quantitative receptor-ligand interaction analysis.
There are currently no reviews for this product.